Benjamin P. Saylor
Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.
FDA approves injectable agent for hypogonadism
FDA approves injectable agent for hypogonadism
The FDA has approved testosterone undecanoate (AVEED) injection for treatment of men with hypogonadism.
Dr. Schoenberg named chair at Albert Einstein
Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, have named Mark Schoenberg, MD, professor and university chair of the department of urology. He will assume his new position in April 2014.
Low-BP diet may offer advantages in cutting stone risk
A diet typically used to lower blood pressure may reduce the risk of kidney stone development, according to a small, recently published study.
Urology Product Preview March 2014
Urology Product Preview March 2014
Drugs and devices in the pipeline from VIVUS, Auxilium Pharmaceuticals, OncoGenex Pharmaceuticals, Veloxis Pharmaceuticals, OPKO Health, and Oxthera AB.
Supplements may raise high-grade prostate cancer risk
High-dose supplementation with both selenium and vitamin E increases the risk of high-grade prostate cancer, according to a recent multicenter study. This risk depends upon a man’s selenium status before taking the supplements.
SGR repeal, PSA access among AUA priorities in ’14
Promotion of strategies for the repeal of the sustainable growth rate formula and preservation of access to appropriate PSA screening are among the AUA’s top legislative priorities for 2014, the association announced.
Large-scale studies of testosterone therapy risks needed
Large-scale studies of testosterone therapy risks needed
Large-scale randomized, controlled trials are needed to determine the true risks and benefits of testosterone therapy in older men, the Endocrine Society said.
ADT affects men’s mental, emotional well-being
Prostate cancer patients treated with androgen deprivation therapy experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life 2 years after treatment, a recent study found.
FDA investigating safety of testosterone products
FDA investigating safety of testosterone products
The FDA said it is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products.
Prostate cancer tests guide treatment, identify aggressive disease
Separate studies at the Genitourinary Cancers Symposium highlighted the utility of prostate cancer tests Prolaris and ConfirmMDx for Prostate Cancer for treatment planning and identifying aggressive disease, respectively.